Effects of some drugs on human cord blood erythrocyte carbonic anhydrases I and II: an in vitro study

Figures & data

Figure 1.  PAGE of the purified CA isozymes. Lane a: Standards: Aldolase (47.5 kDa), E. coli triosephosphate isomerase (32.5 kDa), soybean trypsin inhibitor (24 kDa), Lane b: hcbCA I, Lane c: hcbCA II.

Table 1.  Purification steps of hcbCA I and II from human cord blood erythrocytes by Sepharose-4B-l tyrosine-sulfanilamide affinity gel chromatography.

Purification Step		Activity (EU/mL)	Total Volume (mL)	Protein (mg/mL)	Total Protein (mg)	Total Activity (EU)	Specific Activity (EU/mg)	Recovery (%)	Purification (Fold)
Hemolysate		151.00	51.00	19.33	985.83	7701.00	7.81	100	1.00
Sepharose-4B-l tyrosine-sulfanilamide affinity gel chromatography	hcbCA I	513.00	11.00	0.46	5.06	5643.00	1115.22	73	142.79
	hcbCA II	856.00	6.00	0.15	0.90	5136.00	5706.67	67	730.69

Table 2.  Inhibitory activities of drugs.

Compound Name	Compound Structure	IC50 hcbCA I (µM)	Ki hcbCA I (µM)	Inhibition type	IC50 hcbCA II (µM)	Ki hcbCA II (µM)	Inhibition type
Ampicillin sulfate		-*	-*	-*	56.8	83.0	Non-competitive
Ceftizoxime		79.4	86.1	Non-competitive	79.1	51.8	Non-competitive
Ceftriaxone		27.1	28.5	Non-competitive	21.0	15.8	Non-competitive
Ranitidine		55.5	54.7	Non-competitive	66.1	29.7	Non-competitive

*The inhibition was not determined.